94E Stock Overview
A clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Zura Bio Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.36 |
| 52 Week High | US$5.50 |
| 52 Week Low | US$1.73 |
| Beta | -0.026 |
| 1 Month Change | -16.90% |
| 3 Month Change | -32.57% |
| 1 Year Change | -37.57% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -72.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| 94E | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.3% | 2.3% | 0.3% |
| 1Y | -37.6% | -14.0% | 6.9% |
Return vs Industry: 94E underperformed the German Biotechs industry which returned -12.8% over the past year.
Return vs Market: 94E underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 94E volatility | |
|---|---|
| 94E Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 94E's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 94E's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 15 | Rob Lisicki | zurabio.com |
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Zura Bio Limited Fundamentals Summary
| 94E fundamental statistics | |
|---|---|
| Market cap | €157.57m |
| Earnings (TTM) | -€41.14m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.8x
P/E RatioIs 94E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 94E income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$42.62m |
| Earnings | -US$42.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 94E perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/01 09:54 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zura Bio Limited is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Matthew Barcus | Chardan Capital Markets, LLC |
| Daniil Gataulin | Chardan Capital Markets, LLC |